In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University Hospitals

www.uhhs.com

Latest From University Hospitals

AstraZeneca Opts In To ROR Gamma T Inhibitor Space With Orca Collaboration

BioMotiv spinout could realize up to $122.5 million under arrangement giving AstraZeneca global option rights to a late-stage preclinical program for producing drugs that regulate production of IL-17.

BioPharmaceutical United Kingdom

Deals Shaping The Medical Industry, November 2014

BioPharmaceutical Medical Device

Collaboration With Torrey Pines Adds To BioMotiv’s Early Momentum

The Cleveland-based biopharma accelerator company signs a $40 million agreement with Torrey Pines Investment to provide early-stage funding and development for innovations emerging from academic research. Previously, BioMotiv raised $46 million from investors to fund its model of accelerating breakthrough discoveries into mid-stage development.

BioPharmaceutical United States

BioMotiv: An Rx For Asset Financing Without The Venture Headache

Backed by a Cleveland family foundation and powerful hospital group, the for-profit BioMotiv wants to do biopharma asset financing on its own terms.

BioPharmaceutical United States
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register